MBRX Data Readout: a positive outcome, +11.4%

On June 30, 2026, Moleculin Biotech, Inc. reached its Data Readout. The result was a positive outcome, and the stock moved +11.4% in the window around the event. It had already run -5.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.